The Bloodline with Blood Cancer United Podcast

What does a myelofibrosis (MF) diagnosis really mean, and how does it fit within a group of conditions called myeloproliferative neoplasms, or MPNs? In this episode, we’re joined by Dr. Tania Jain of Johns Hopkins Sidney Kimmel Comprehensive Cancer Center in Baltimore, MD, who helps break it all down in a clear and approachable way.

She discusses how myelofibrosis affects the bone marrow, common symptoms to watch for, and ...

Some people with chronic lymphocytic leukemia (CLL) may feel well day to day, but that doesn’t mean life stays the same. In this episode, we hear from Annette Holloway, a clinical psychologist living with CLL, as she shares how her diagnosis, treatment decisions, and side effects have shaped her daily life. Also joining us is Elise Curry, RN, OCN, a Clinical Trial Nurse Navigator at Blood Cancer United’s Clinical Trial ...

Acute myeloid leukemia (AML) is a complex diagnosis, and it can be difficult to know what to expect in those early conversations after diagnosis. In this episode, we speak with Dr. Rebecca Olin from the University of California, San Francisco (UCSF), who helps explain what AML is and how care is approached today.

Dr. Olin walks us through how doctors evaluate AML, what factors influence treatment decisions, and how therapies &nd...

A cancer diagnosis in your 20s or 30s can raise questions most people never expect to face so early in life.

In this episode, we speak with Chris Pagliarulo, who was diagnosed with Hodgkin lymphoma at the age of 29, about the medical, emotional, and practical realities of cancer during early adulthood. We explore issues that are especially relevant for adolescent and young adult (AYA) patients, including delayed diagnosis, f...

With so many new advances in acute lymphoblastic leukemia (ALL), understanding today’s treatment landscape can give patients a clearer, more hopeful outlook.

In this episode, we speak with Marlise Luskin, MD of the Dana-Farber Cancer Institute, about what adults should know when facing a diagnosis of acute lymphoblastic leukemia. Dr. Luskin helps listeners understand how ALL develops, how subtypes are identified, and why g...

Multiple myeloma can feel unfamiliar and overwhelming at first, but today’s advances tell a much brighter story.

In this episode, Dr. Andrew Yee of Massachusetts General Hospital explains what myeloma is, how it’s diagnosed, and why new treatment options, from four-drug regimens to CAR T-cell therapy and bispecific antibodies, are transforming patient outcomes. With enthusiasm and relatable analogies, he highlights h...

CAR T‑cell therapy is redefining what personalized cancer treatment can look like, offering real promise for patients and families.

In this episode, we speak with Dr. Richard Maziarz and CAR T Nurse Coordinator Bashi Ratterree of Oregon Health & Science University (OHSU). Together, they explain how CAR T‑cell therapy works, who may be eligible, what patients can expect during treatment and recovery, and the promising advance...

Cutaneous T‑cell lymphoma (CTCL) is a rare condition that often raises important questions for patients and families.

In this episode, we sit down with Dr. Stefan Barta, of the University of Pennsylvania, to bring clarity to what CTCL is, how it’s diagnosed, and what patients can expect from staging and treatment. Dr. Barta breaks down the differences between CTCL subtypes, explains why diagnosing someone can take time, an...

Curious about what’s new in the world of myelodysplastic syndromes (MDS)? We’re bringing you the latest insights straight from one of the field’s leading experts.

In this episode, we speak with Dr. Mikkael Sekeres, of the Sylvester Comprehensive Cancer Center at University of Miami Health. Recorded onsite at the 2025 ASH (American Society of Hematology) Annual Meeting and Exposition, this conversation explores ...

In this episode, we sit down with Ann Grace MacMullan, Director of Integrative Wellness at the International Waldenstrӧm’s Macroglobulinemia Foundation (IWMF), to explore how wellness can become a powerful part of life after a cancer diagnosis. Ann Grace shares practical, calming techniques, including breathing exercises, “Bee’s Breath”, and guided meditation, that you can do anywhere to reduce stress and fe...

Non-Hodgkin lymphoma (NHL) can sound overwhelming, but what does it really mean for patients and families? In this episode, we speak to Dr. Jean Koff of Winship Cancer Institute of Emory University, who breaks down the big picture of NHL: what it is, how it’s an umbrella term for multiple subtypes, and what today’s treatments and tomorrow’s innovations could mean for you. From understanding subtypes and staging to...

Nutrition plays a powerful role in supporting children through cancer treatment, but it’s not always easy for caregivers to know what’s best, especially when there are taste changes, appetite shifts, and treatment side effects.

In this episode, we sit down with Michell Fullmer, a registered dietitian at Nemours Children’s Hospital, to share practical insights that simplify nutrition during cancer care, reduce m...

In this episode, we are joined by Dr. Abdulraheem Yacoub of The University of Kansas Cancer Center to discuss myeloproliferative neoplasms (MPN), a group of rare blood cancers that affect how blood cells are produced. We explore what MPNs are, the most common types, and the signs and symptoms that lead to diagnosis. We also answer real questions from members of our MPN online chat community, covering topics like life expectancy, ge...

When cancer enters a family, it changes everything – routines, roles, and relationships.

In this episode, we talk with Lindsey and Thomas Kealey about what it means to navigate cancer together as a care partner and patient. From unexpected diagnoses to months spent living in a hospital room, Lindsey shares how she balanced caregiving, work, and self-care while learning to hold space for difficult emotions. Together, they o...

MRD (minimal/measurable residual disease) testing is changing the way doctors understand and monitor blood cancers.  In this episode, we talk with Dr. John Burke of the Rocky Mountain Cancer Center about how MRD testing works, what the results mean to patients and their care teams, and how ongoing clinical research is helping shape more personalized and hopeful approaches to treatment.